P
Pierre-Alain Vitte
Researcher at Merck Serono
Publications - 31
Citations - 1739
Pierre-Alain Vitte is an academic researcher from Merck Serono. The author has contributed to research in topics: Fusion protein & Receptor. The author has an hindex of 14, co-authored 31 publications receiving 1661 citations.
Papers
More filters
Journal ArticleDOI
Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis
Montserrat Camps,Thomas Rückle,Hong Ji,Vittoria Ardissone,Felix Rintelen,Jeffrey P. Shaw,Chiara Ferrandi,Christian Chabert,Corine Gillieron,Bernard Françon,Thierry Martin,Denise Gretener,Dominique Perrin,Didier Leroy,Pierre-Alain Vitte,Emilio Hirsch,Matthias P. Wymann,Rocco Cirillo,Matthias Schwarz,Christian Rommel +19 more
TL;DR: It is shown that Pik3cg−/− mice are largely protected in mouse models of rheumatoid arthritis; this protection correlates with defective neutrophil migration, further validating PI3Kγ as a therapeutic target.
Journal ArticleDOI
Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats
Chiara Ferrandi,Rossana Ballerio,Pascale Gaillard,Claudio Giachetti,Sonia Carboni,Pierre-Alain Vitte,Jean-Pierre Gotteland,Rocco Cirillo +7 more
TL;DR: It is demonstrated that blocking the JNK pathway may represent a novel therapeutic approach for treating myocardial ischemia/reperfusion‐induced cardiomyocyte death and beneficial effects on infarct size are investigated.
Journal ArticleDOI
Bax Channel Inhibitors Prevent Mitochondrion-mediated Apoptosis and Protect Neurons in a Model of Global Brain Ischemia
Claudio Hetz,Claudio Hetz,Pierre-Alain Vitte,Agnes Bombrun,Tatiana K. Rostovtseva,Sylvie Montessuit,Agnes Hiver,Matthias Schwarz,Dennis Church,Stanley J. Korsmeyer,Jean-Claude Martinou,Bruno Antonsson +11 more
TL;DR: The Bax channel inhibitors prevented cytochrome c release from mitochondria, inhibited the decrease in the mitochondrial membrane potential, and protected cells against apoptosis and protected neurons in an animal model of global brain ischemia.
Journal ArticleDOI
Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.
Pascale Gaillard,Isabelle Jeanclaude-Etter,Vittoria Ardissone,Steve Arkinstall,Yves Cambet,Montserrat Camps,Christian Chabert,Dennis Church,Rocco Cirillo,Denise Gretener,Serge Halazy,Anthony Nichols,Cedric Szyndralewiez,Pierre-Alain Vitte,Jean-Pierre Gotteland +14 more
TL;DR: The in vitro and in vivo anti-inflammatory potential of this new JNK inhibitor was investigated and found to demonstrate efficacy per oral route in an experimental model of rheumatoid arthritis (RA).
Journal ArticleDOI
AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties.
Sonia Carboni,Agnes Hiver,Cedric Szyndralewiez,Pascale Gaillard,Jean-Pierre Gotteland,Pierre-Alain Vitte +5 more
TL;DR: A small molecule, AS601245 (1,3-benzothiazol-2-yl (2-{[2-(3-pyridinyl) ethyl] amino}-4 pyrimidyl) acetonitrile), which has been shown to inhibit the JNK signaling pathway, promotes cell survival after cerebral ischemia.